Vidcast:  https://youtu.be/EaG0OrjId0U

 

Those who survive CoVid not only have more anti-viral antibodies, but those they do have are of higher quality.  Harvard immunologists draw this conclusion from their studies of 193 hospitalized CoVid patients comparing those surviving moderate to severe disease with those who perished.

 

Those who survived CoVid developed antibodies that could effectively bind to spike protein and prevent the virus from invading cell after cell. They also brewed  antibodies that bind to the Fc sites on killer lymphocytes and trigger them to flush away virus-infected cells that would release ever more virus.

 

This new information will guide vaccine developers to produce agents that evoke even more powerful protective antibodies.

 

https://www.cell.com/cell/pdf/S0092-8674(20)31459-8.pdf?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0092867420314598%3Fshowall%3Dtrue

 

#covid #antibodies #spikeprotein #killercells